Podcasts about intranasal

In this episode, we explore Oxytocin and Vasopressin's vast roles in Human Biology. We time travel to cover the evolution of the two molecules and learn about their functions with developing and socializing. Oxytocin and Vasopressin are dynamic molecules whereby they are Peptides and Hormones. In addition, we cover previously discussed brain regions and how the molecules work alongside key Neuromodulators like Serotonin and Dopamine.Social Reward https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214365/Social Reward Requires Oxytocin and Serotonin in Nucleus Accumbens (Parvo Path) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091761/Magnocellular and Parvocellular social Information Processing https://www.cell.com/neuron/fulltext/S0896-6273(20)30770-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0896627320307704%3Fshowall%3DtrueMagnocellular and Parvocellular https://onlinelibrary.wiley.com/doi/10.1111/jne.12284Meta-Analysis of Intranasal https://pubmed.ncbi.nlm.nih.gov/?term=intranasal+oxytocin+autism&sort=pubdate&filter=pubt.meta-analysishttps://pubmed.ncbi.nlm.nih.gov/33400920/Intranasal Review https://pubmed.ncbi.nlm.nih.gov/38579916/(0:00) Intro; Oxytocin and Vasopressin; Episode Objectives(2:46) Oxytocin and Vasopressin; 700 million year time travel (Phylogeny)(4:12) Peptides and Hormones; Modes of Transmission- Endocrine, Paracrine, Synaptic(6:35) Proteins and Peptides; Amino Acids and Aromatic Amino Acids and Light(8:58) Magnocellular and Parvocellular(12:33) Roles of Oxytocin and Vasopressin and connections to various Brain Regions(22:20) Scientific Literatures(27:12) Oxytocin and Serotonin; 1) Reward Processing, 2) Fear Response, 3) Social-Emotional Processing(30:07) Oxytocin and Dopamine(31:08) Dopamine Receptors(31:37) GABA(33:57) Intranasal Oxytocin(36:08) Take aways from Intranasal Literature(37:24) Biggest Take Away (Magnocellular versus Parvocellular and Intranasal Administration)email: info.fromthespectrum@gmail.com

Dr. Thomas Chen, Founder, CEO, and CSO of NeOnc Technologies, is working on the challenge of delivering drugs across the blood-brain barrier by using an intranasal delivery approach to target brain cancers. This delivery platform leverages the cranial nerve to transport the drugs directly to the brain, bypassing the blood-brain barrier. Genomic analysis of the long-surviving patients in the phase one trial revealed a common genetic mutation, informing the trial design for the next phase. Thomas explains, "So our platform is what we call intranasal delivery. And with the intranasal delivery, we're not trying to cross the blood-brain barrier. We're trying to cross over it. And how we're doing that is doing the delivery of the drug via what we call the C nerves. Now the cranial nerves are, we have 12 cranial nerves in our brain. These cranial nerves have various functions, but the cranial nerves involved with the nasal brain delivery are the first and the fifth cranial nerves. The first cranial nerve is what we call the olfactory nerve. That's the nerve that's responsible for smell. The fifth cranial nerve is called the trigeminal nerve, which involves facial sensation and allows us to chew."   "So what happens is that when we want to deliver the drug to the brain cancer, we have the patient inhale it. When the patient inhales, it goes through the nose, and through the olfactory nerve, it goes to the brain. Usually, that molecule then absorbs in the spinal brain and then circulates to the target, in this case, brain cancer. Now you know how powerful that cranial nerve is from the standpoint of what it does when you smell something, that scent, that odor gets transported from the olfactory nerve to our brain. And that's basically what we're doing. We're taking something external to the brain, allowing the cranial nerve to absorb and transport it to the brain." #NeOnc #BloodBrainBarrier #BBB #BrainCancer #DrugDelivery neonc.com Download the transcript here

Dr. Thomas Chen, Founder, CEO, and CSO of NeOnc Technologies, is working on the challenge of delivering drugs across the blood-brain barrier by using an intranasal delivery approach to target brain cancers. This delivery platform leverages the cranial nerve to transport the drugs directly to the brain, bypassing the blood-brain barrier. Genomic analysis of the long-surviving patients in the phase one trial revealed a common genetic mutation, informing the trial design for the next phase. Thomas explains, "So our platform is what we call intranasal delivery. And with the intranasal delivery, we're not trying to cross the blood-brain barrier. We're trying to cross over it. And how we're doing that is doing the delivery of the drug via what we call the C nerves. Now the cranial nerves are, we have 12 cranial nerves in our brain. These cranial nerves have various functions, but the cranial nerves involved with the nasal brain delivery are the first and the fifth cranial nerves. The first cranial nerve is what we call the olfactory nerve. That's the nerve that's responsible for smell. The fifth cranial nerve is called the trigeminal nerve, which involves facial sensation and allows us to chew."   "So what happens is that when we want to deliver the drug to the brain cancer, we have the patient inhale it. When the patient inhales, it goes through the nose, and through the olfactory nerve, it goes to the brain. Usually, that molecule then absorbs in the spinal brain and then circulates to the target, in this case, brain cancer. Now you know how powerful that cranial nerve is from the standpoint of what it does when you smell something, that scent, that odor gets transported from the olfactory nerve to our brain. And that's basically what we're doing. We're taking something external to the brain, allowing the cranial nerve to absorb and transport it to the brain." #NeOnc #BloodBrainBarrier #BBB #BrainCancer #DrugDelivery neonc.com Listen to the podcast here

Send us a text“If that medicine is associated with fear of an injection, then we are giving the impression that a diagnosis of food allergy is worse than a life sentence.” — Dr. Paul TurnerWhen it comes to managing anaphylaxis, epinephrine is the gold standard. But even with its life-saving potential, misconceptions abound, and newer delivery methods like nasal and sublingual formulations are raising questions for allergists and patients alike. In this episode, Dr. Mariam Hanna sits down with Dr. Paul Turner, pediatric allergist, clinical immunologist, and global expert on anaphylaxis, to explore the science, controversies, and clinical realities surrounding epinephrine use.On this episode:Anaphylaxis demystified: Why the "ABC" symptoms (airway, breathing, circulation) are crucial for timely diagnosis.Epinephrine explained: How it works, why timing matters, and when it's not enough.Alternative delivery methods: Intranasal and sublingual epinephrine—why Dr. Turner is skeptical about their use in clinical practice without robust evidence of efficacy.When epi fails: Understanding the limitations of autoinjectors in severe reactions and the role of IV infusions.Improving patient confidence: Strategies for addressing fears and teaching appropriate use to improve outcomes.Whether you're an allergist navigating these evolving treatment landscapes or a clinician seeking clear guidance for patient care, this episode provides critical insights and practical advice. Tune in to strengthen your understanding of epinephrine's role in anaphylaxis management and gain clarity on when—and how—it should be used.Visit the Canadian Society of Allergy and Clinical ImmunologyFind an allergist using our helpful toolFind Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_caThe Allergist is produced for CSACI by PodCraft Productions

Destaque no Prêmio Nobel de Medicina de 2023, a tecnologia de RNA mensageiro é uma das grandes apostas para o desenvolvimento de vacinas, oferecendo potencial para combater uma variedade de doenças com maior eficiência.   Também são discutidas tecnologias emergentes, como a imunização intranasal, que pode revolucionar a forma como as vacinas são administradas, e avanços na criação de vacinas contra vírus desafiadores como o HIV, além de abordagens para doenças negligenciadas e até mesmo o câncer.  Neste episódio do podcast de Biotech and Health, Camila Pepe e Laura Murta conversam sobre esses temas com o médico imunologista Jorge Kalil, professor da Faculdade de Medicina da USP, diretor do Laboratório de Imunologia do InCor e ex-diretor do Butantan.  Podcast Biotech and Health: O futuro conectado, agora em vídeo!

Send us a textOutcomes after intranasal human milk therapy in preterm infants with intraventricular hemorrhage.Gallipoli A, Unger S, El Shahed A, Fan CS, Signorile M, Wilson D, Hoban R.J Perinatol. 2024 Oct 9. doi: 10.1038/s41372-024-02147-3. Online ahead of print.PMID: 39384614As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

El departamento de salud de Elda fue pionero en la vacunación frente a la gripe en los centros docentes, que culminó con éxito de participación

What is the impact of central insulin on muscle sympathetic nerve activity (MSNA) and vascular conductance in the absence of peripheral insulin delivery? Listen as Associate Editor Dr. Jason Carter (Baylor University) interviews authors Neil McMillan and Dr. Jackie Limberg (both at University of Missouri), along with expert Dr. Manda Keller-Ross (University of Minnesota), about the new Short Report by McMillan et al. To gain a better understanding of the central sympathoexcitatory effects of insulin in humans, the authors recruited two groups of young, healthy individuals. One group served as a time control and the other group received intranasal insulin administration. McMillan et al. measured MSNA from the fibular nerve, combined with continuous monitoring of blood pressure and leg blood flow, before and after insulin administration. Limberg, McMillan and co-authors found that only the individuals who received insulin exhibited an increase in efferent sympathetic nervous system activity, which was coupled with peripheral vasoconstriction and increases in arterial blood pressure. How does this research influence our mechanistic understanding of the sympathetic and hemodynamic response to insulin? Listen now to find out.   Neil J. McMillan, Dain W. Jacob, Brian Shariffi, Jennifer L. Harper, Glen E. Foster, Camila Manrique-Acevedo, Jaume Padilla, and Jacqueline K. Limberg Effect of acute intranasal insulin administration on muscle sympathetic nerve activity in healthy young adults Am J Physiol Heart Circ Physiol, published July 3, 2024. DOI: 10.1152/ajpheart.00253.2024

Contributor: Taylor Lynch, MD Educational Pearls: Opioid Epidemic- quick facts Drug overdoses, primarily driven by opioids, have become the leading cause of accidental death in the U.S. for individuals aged 18-45. In 2021, opioids were involved in nearly 75% of all drug overdose deaths The rise of synthetic opioids like fentanyl, which is much more potent than heroin or prescription opioids, has played a major role in the increase in overdose deaths What is Narcan AKA Naloxone? Competitive opioid antagonist. It sits on the receptor but doesn't activate it. When do we give Narcan? Respiratory rate less than 8-10 breaths per minute Should you check the pupils? An opioid overdose classically presents with pinpoint pupils BUT… Hypercapnia from bradypnea can normalize the pupils Taking other drugs at the same time like cocaine or meth can counteract the pupillary effects Basilar stroke could also cause small pupils, so don't anchor on an opioid overdose How does Narcan affect the body? Relatively safe even if the patient is not experiencing an opioid overdose. So when in doubt, give the Narcan. What if the patient is opioid naive and overdosing? Use a large dose given that this patient is unlikely to withdraw 0.4-2 mg every 3-5 minutes What if the patient is a chronic opioid user Use a smaller dose such as 0.04-0.4 mg to avoid precipitated withdrawal How fast does Narcan work? Given intravenously (IV), onset is 1-2 min Given intranasal (IN), onset is 3-4 min Given intramuscularly (IM), onset is ~6 min Duration of action is 60 mins, with a range of 20-90 minutes How does that compare to the duration of action of common opioids? Heroine lasts 60 min Fentanyl lasts 30-60 min, depending on route Carfentanyl lasts ~5 hrs Methadone lasts 12-24 hrs So we really need to be conscious about redosing How do you monitor someone treated with Narcan? Pay close attention to the end-tidal CO2 to ensure that are ventilating appropriately Be cautious with giving O2 as it might mask hypoventilation Watch the respiratory rate Give Narcan as needed Observe for at least 2-4 hours after the last Narcan dose Larger the dose, longer the observation period Who gets a drip? If they have gotten ~3 doses, time to start the drip Start at 2/3rds last effective wake-up dose Complications Flash pulm edema 0.2-3.6% complication rate Might be from the catecholamine surge from abrupt wake-up Might also be from large inspiratory effort against a partially closed glottis which creates too much negative pressure Treat with BIPAP if awake and intubation if not awake Should you give Narcan in cardiac arrest? Short answer no. During ACLS you take over breathing for the patient and that is pretty much the only way that Narcan can help Just focus on high quality CPR References https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#:~:text=Drug%20overdose%20deaths%20involving%20prescription,of%20deaths%20declined%20to%2014%2C716. Elkattawy, S., Alyacoub, R., Ejikeme, C., Noori, M. A. M., & Remolina, C. (2021). Naloxone induced pulmonary edema. Journal of community hospital internal medicine perspectives, 11(1), 139–142. https://doi.org/10.1080/20009666.2020.1854417 van Lemmen, M., Florian, J., Li, Z., van Velzen, M., van Dorp, E., Niesters, M., Sarton, E., Olofsen, E., van der Schrier, R., Strauss, D. G., & Dahan, A. (2023). Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest. Anesthesiology, 139(3), 342–353. https://doi.org/10.1097/ALN.0000000000004622 Yousefifard, M., Vazirizadeh-Mahabadi, M. H., Neishaboori, A. M., Alavi, S. N. R., Amiri, M., Baratloo, A., & Saberian, P. (2019). Intranasal versus Intramuscular/Intravenous Naloxone for Pre-hospital Opioid Overdose: A Systematic Review and Meta-analysis. Advanced journal of emergency medicine, 4(2), e27. https://doi.org/10.22114/ajem.v0i0.279 Summarized by Jeffrey Olson MS2 | Edited by Meg Joyce & Jorge Chalit, OMSII

In this episode, we explore Oxytocin and Vasopressin's vast roles in Human Biology. We time travel to cover the evolution of the two molecules and learn about their functions with developing and socializing. Oxytocin and Vasopressin are dynamic molecules whereby they are Peptides and Hormones. In addition, we cover previously discussed brain regions and how the molecules work alongside key Neuromodulators like Serotonin and Dopamine.Social Reward https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214365/Social Reward Requires Oxytocin and Serotonin in Nucleus Accumbens (Parvo Path) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091761/Magnocellular and Parvocellular social Information Processing https://www.cell.com/neuron/fulltext/S0896-6273(20)30770-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0896627320307704%3Fshowall%3DtrueMagnocellular and Parvocellular https://onlinelibrary.wiley.com/doi/10.1111/jne.12284Meta-Analysis of Intranasal https://pubmed.ncbi.nlm.nih.gov/?term=intranasal+oxytocin+autism&sort=pubdate&filter=pubt.meta-analysishttps://pubmed.ncbi.nlm.nih.gov/33400920/Intranasal Review https://pubmed.ncbi.nlm.nih.gov/38579916/(0:00) Intro; Oxytocin and Vasopressin; Episode Objectives(2:46) Oxytocin and Vasopressin; 700 million year time travel (Phylogeny)(4:12) Peptides and Hormones; Modes of Transmission- Endocrine, Paracrine, Synaptic(6:35) Proteins and Peptides; Amino Acids and Aromatic Amino Acids and Light(8:58) Magnocellular and Parvocellular(12:33) Roles of Oxytocin and Vasopressin and connections to various Brain Regions(22:20) Scientific Literatures(27:12) Oxytocin and Serotonin; 1) Reward Processing, 2) Fear Response, 3) Social-Emotional Processing(30:07) Oxytocin and Dopamine(31:08) Dopamine Receptors(31:37) GABA(33:57) Intranasal Oxytocin(36:08) Take aways from Intranasal Literature(37:24) Biggest Take Away (Magnocellular versus Parvocellular and Intranasal Administration)email: info.fromthespectrum@gmail.com

Immune presents three stories: intranasal neomycin and antiviral immunity, sexual dimorphism in skin immunity, and maternal diet changes infant microbes that alter gut DC responses and respiratory health. Hosts: Stephanie Langel, Cynthia Leifer, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Intranasal neomycin as antiviral (PNAS) Sexual dimorphism in skin immunity (Science) Maternal diet and infant respiratory health (Immunity) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

In this episode of our ongoing miniseries "Push Dose Pearls," we discuss the use of intranasal medications in the emergency department with Chris Adams, an ED clinical pharmacist at UC Davis. We talk about the benefits of intranasal administration, intranasal medications, and advantages for pediatric patients. Did this episode change your practice? Let us know on social media @empulsepodcast or at ucdavisem.com Hosts: Dr. Sarah Medeiros, Associate Professor of Emergency Medicine at UC Davis Dr. Julia Magaña, Associate Professor of Pediatric Emergency Medicine at UC Davis Guests: Christopher Adams, PharmD, Emergency Department Senior Clinical Pharmacist and Assistant Professor at UC Davis *** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.    

Dr. Zahra Figueredo explains how to implant the Stem Cells into patients. Few examples: Intravenous, Intrathecal, Intranasal aspiration, Intra-Articular, Intra-Muscular, Combined Manner, Local Injections for joints, cosmetic and organs. Listen to this interesting podcast. _________________________________________________ Could Dr. Zahra's Natural and Unique Stem Cell Therapy Transform Your Life? "My heart and soul sing when we see what an incredible impact we can make on the lives of our patients and their families with our natural and comprehensive stem cell therapies." Dr. Zahra Figueredo. Canadian Dr. Zahra Figueredo has successfully treated 1,000+ patients from the USA and Canada suffering with hundreds of different health problems in her Stem Cell Healing Institute in Guatemala - 'the land of eternal Spring' - with her safe, comprehensive, non-surgical and innovative stem cell therapies. It's important to note that Dr. Zahra's powerful stem cell combination therapy is NOT available anywhere in the USA or Canada. What To Do Now?New Patient? - Learn how Dr. Zahra's combined stem cell healing could transform your life. Please send us an email. info@stemcellhealinginstitute.com For more information on stem cell treatment please visit our website

In his weekly clinical update, Dr. Griffin begins with discussing if the antibiotic neomycin is really a pan-antiviral countermeasure, then reviews the recent statistics on SARS-CoV-2 infection before deep diving into if shedding and the rapid antigen test results correlate, the guidelines for spring administration of COVID vaccines boosters, whether COVID booster associates with the long COVID prevalence, discusses the emergency use application of a pre-exposure prophylactic, revised guidelines for how to treat respiratory viral infection guidelines by the CDC, the caveats for improper use of antibiotics to treat SARS-CoV-2 (a viral infection), continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if administration of an anti-immunoglobulin E monoclonal antibody can be used for COVID-19 treatment, if inhibiting T-cell activation will reduce secretion and production of inflammatory cytokines including IL-6, if changes in the gut microbiome associate with post -acute COVID-19 syndrome, and the pulmonary and neurologic determinants of long COVID-19 such as the presence of neurofilament light chain in plasma. For more information about this body of work, listen to TWiV 1088. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Intranasal antibiotic evokes antiviral response (PNAS) COVID-19 national trend (CDC) COVID-19 deaths (CDC) SARS-CoV-2 shedding vs rapid antigen test performance (MMWR) Spring vaccineadvice (CIDRAP) Older adult spring booster available (CDC) Advisory committee for immunization practices slides (CDC) Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC) COVID-19 booster take: cross-sectional study (Vaccine) EUA for pemgarda (FDA) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (IDSociety) Overuse ofantibiotics for COVID-19: a viral disease (European Society of Clinical Microbiology and Infectious Diseases) Can you believe that antibiotics are ineffective against a viral illness (NKT Institute) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (IDSociety) Outpatient treatment with concomitant vaccine-boosted convalescent plasma (mBio) Updated respiratory virus guidances (CDC) What do when your heathcare provider is infected with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Immunologic antiviral therapy with omalizumab (OFID) Abatacept pharmacokinetics and exposure response (JAMA Network Open) Long COVID evidence based review TWiV shout out (TWiV 1088) Gut microbiome and post-acute COVID-19 syndrome, ugh? (Cell Host and Microbe) Pulmonary long COVID (JCI Insight) Neurofilament light chain in long COVID019 neurocognitive symptoms (Molecular Psychiatry) Contribute to our Floating Doctors fundraiser Letters read on TWiV 1110 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Dr. Zahra Figueredo explains how to implant the Stem Cells into patients. Few examples: Intravenous, Intrathecal, Intranasal aspiration, Intra-Articular, Intra-Muscular, Combined Manner, Local Injections for joints, cosmetic and organs. Listen to this interesting podcast. _________________________________________________ Could Dr. Zahra's Natural and Unique Stem Cell Therapy Transform Your Life? "My heart and soul sing when we see what an incredible impact we can make on the lives of our patients and their families with our natural and comprehensive stem cell therapies." Dr. Zahra Figueredo. Canadian Dr. Zahra Figueredo has successfully treated 1,000+ patients from the USA and Canada suffering with hundreds of different health problems in her Stem Cell Healing Institute in Guatemala - 'the land of eternal Spring' - with her safe, comprehensive, non-surgical and innovative stem cell therapies. It's important to note that Dr. Zahra's powerful stem cell combination therapy is NOT available anywhere in the USA or Canada. What To Do Now?New Patient? - Learn how Dr. Zahra's combined stem cell healing could transform your life. Please send us an email. info@stemcellhealinginstitute.com For more information on stem cell treatment please visit our website

Dr. Soonjo Hwang (University of Nebraska Medical Center) joins AJP Audio to discuss the response to intranasally-administered oxytocin in youths with severe irritability. 00:56     Hwang interview 02:09     Effects of oxytocin 05:45     Intranasal oxytocin 07:04     Potential adverse effects of oxytocin 08:08     Imaging 08:58     Preliminary investigations and clinical implications 09:51     Limitations 10:14     Further research 11:00     Kalin interview 11:33     Hwang et al. 14:43     Leibenluft et al. 15:39     Aggarwal et al. 18:22     Pezzoli et al. 21:34     Kendler et al. 23:30     Hou et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

We hear updates from leaders in the animal health and supplies business, Merck Animal Health and Ritchey Livestock ID.  Plus we have the latest cattle and livestock news, bull sale updates, markets, hay auctions and lots more on this all new episode of The Ranch It Up Radio Show. Be sure to subscribe on your favorite podcasting app or on the Ranch It Up Radio Show YouTube Channel. EPISODE 176 DETAILS Merck Animal Health has been a leader in animal health products.  Hear how a proper calfhood vaccination program can set your newborn calves up for success later in life.  Livestock identification is a must and producers need to have ear tags that don't fade, don't break and are easy to read.  We hear an update from the tag that never fades, Ritchey Livestock ID and Ritchey Tags! Meat product labeling (COOL) is back on discussion.  Country of Origin Labeling has been a discussion point for a long time.  Hear reaction from consumer groups in our news segment.  We have the latest sale reports and cattle sales.  Plus hear a weekly market recap with Kirk Donsbach with Stone X Financial! MERCK ANIMAL HEALTH Optimizing Vaccine Efficacy In Animal Health:  Best Practices & Considerations Vaccines play a crucial role in safeguarding animal health by bolstering their immune systems against various pathogens. Understanding proper storage, handling, and administration of vaccines is essential to ensure their effectiveness. Key Points: 1. Importance of Vaccines: Vaccines are preventive tools designed to prepare an animal's immune system to combat diseases caused by bacteria, viruses, or protozoa.   2. Proper Handling and Storage: Deviations from label instructions regarding storage, transportation, and handling can compromise vaccine efficacy. Vaccines should be stored in refrigerators maintaining optimal temperatures.   3. Factors Affecting Efficacy: Nutritional deficiencies, environmental stressors, and preexisting health conditions can influence an animal's response to vaccination.   4. Administration Best Practices: Proper reconstitution, mixing, and administration techniques are crucial for vaccine effectiveness.   5. Herd Veterinarian Guidance: Tailoring vaccination programs to specific herd needs and consulting with a veterinarian ensures optimal protection.   6. Vaccine Types and Revaccination: Understanding differences between modified live virus (MLV) and killed virus (KV) vaccines and adhering to recommended revaccination schedules are vital.   7. Calfhood Vaccination Programs: Initiating comprehensive vaccination programs early in a calf's life, especially during pre weaning stages, is essential for disease prevention.   8. Essential Components: Commonly included vaccines protect against respiratory diseases and clostridial infections, but specific vaccine decisions should be made with veterinary consultation.   9. Heifer Vaccination: Vaccination programs for replacement heifers should mirror those for mature cows, with consideration for reproductive diseases.   10. Pre Breeding and Pre Calving Vaccinations: Timing and selection of vaccines are critical to ensure adequate immunity transfer and protection for newborn calves.   11. Bull Vaccination: Bulls should receive similar vaccines as the cow herd, with exceptions such as brucellosis vaccination. Effective vaccine utilization requires adherence to proper storage, handling, and administration practices, along with tailored vaccination programs guided by veterinary expertise. By implementing these strategies, livestock producers can enhance animal health and productivity while mitigating disease risks. ALLFLEX® CleanVax™  Nozzles and Shields for Intranasal Vaccination Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new ALLFLEX® CleanVax™ nozzles and shields for clean, fast and convenient administration of intranasal vaccines to cattle. The CleanVax intranasal vaccination system includes shorter nozzles that are less invasive than conventional cannulas, as well as clear plastic disposable shields that can be replaced between animals or groups of animals for more hygienic administration. “CleanVax nozzles and shields optimize every aspect of the intranasal vaccination process for confidence in a clean, consistent dose every time,” said Jonathon Townsend, D.V.M., Ph.D., dairy technical services for Merck Animal Health. “The system is simple to use and enhances calf comfort, hygiene and consistency, making it easier on both the calf and caregiver.” The following are the advantages of the CleanVax intranasal vaccination system: Calf-friendly, shorter nozzles minimize discomfort; Atomizer tips ensure even distribution across mucosal surfaces and reduce product drip; Easy-to-use nozzles attach to any brand of syringe or Luer lock applicator gun; Hygienic shields add a layer of protection and enhance biosecurity. “CleanVax nozzles and shields are designed to make intranasal vaccine administration more hygienic, calf-friendly and consistent,” Dr. Townsend added. “As a leader in intranasal vaccination technologies, Merck Animal Health continues to advance cattle health and production with innovative and effective solutions for cattle producers.” Intranasal vaccines available from Merck Animal Health include BOVILIS® NASALGEN® 3-PMH, BOVILIS NASALGEN 3, BOVILIS NASALGEN IP, BOVILIS CORONAVIRUS and BOVILIS ONCE PMH® IN. ALLFLEX CleanVax products are now available through your Merck Animal Health representative or ALLFLEX supplier. Learn more at MAHcattle.com. RITCHEY LIVESTOCK ID The tag that never fades Tag longevity sets us apart at Ritchey.  Livestock ID information is permanently engraved into the tag and readable for the lifetime of the animal.  After all, what's a tag work that fades? Absolutely nothing. American Made, Family Owned Being American made and family owned is what makes us unique at Ritchey Livestock ID.  It inherently feels right to be making livestock ID tags in the United States. Make Your Mark Ritchey livestock tags are the only tag that allows you to quickly engrave ID information yourself.  You can proudly display your family's brand or engrave a last second tag at the chute.  The power is yours!   COW COUNTRY NEWS USDA Finalizes Voluntary “Product Of USA” Labeling Rule USDA Secretary Tom Vilsack on Monday announced the finalization of a rule to align the voluntary “Product of the USA” label claim with consumer expectations of what the claim means. The designation allows the voluntary “Product of USA” or “Made in the USA” label claim to be used on meat, poultry and egg products only when they come from animals born, raised, slaughtered and processed in the United States. The final rule aims to prohibit misleading U.S. origin labeling in the marketplace and helps ensure that the information that consumers receive about where their food comes from is based on facts. The labels will continue to maintain their voluntary status for use on products and also will be eligible for generic label approval, which removes the need for pre-approval by USDA, but requires manufacturers to maintain documentation to support the claim. Last summer, the country of origin labeling rules (COOL), as they were proposed, covering meat, poultry and egg products, were criticized by the Canadian government and the National Pork Producers Council because they included specific regulations on where the animals were raised, which were not part of earlier versions of the rule. Companies that use the “Made in the USA” claim will need to comply with the final rule by Jan. 1, 2026, but are being encouraged to do so as soon as possible. The National Cattlemen's Beef Association's Executive Director of Government Affairs Kent Bacus released the following statement on the USDA's finalized rule on the "Product of USA" label by saying, “NCBA has been committed to finding solutions to this problem ever since a producer-led NCBA working group raised the alarm, years ago, that imported beef could be mislabeled as a Product of the USA incorrectly at the end of the supply chain. We appreciate USDA's effort to address this loophole. During the implementation period, NCBA's focus will remain on ensuring that these changes result in the opportunity for producer premiums while remaining trade compliant.”   UPCOMING BULL SALES ANGUS CHAROLAIS HEREFORD GELBVIEH BALANCER RED ANGUS SIMMENTAL SIMANGUS Weber Land & Cattle:  March 12, 2024, Lake Benton, Minnesota Sundsbak Farms: March 16, 2024, Des Lacs, North Dakota Hidden Angus: March 17, 2024, Sebeka, Minnesota Wheatland Cattle Company:  March 21, 2024, Bienfait, Saskatchewan, Canada Miller Angus Farms: March 25, 2024, Watertown, South Dakota L 83 Ranch: March 26, 2024, Mandan, ND Vollmer Angus Ranch: April 2, 2024, Wing, North Dakota A & B Cattle:  April 4, 2024, Bassett, Nebraska Montgomery Ranch: April 14, 2024, Carrington, North Dakota Jorgensen Farms:  April 15, 2024, Ideal, South Dakota BULL SALE REPORT & RESULTS Churchill Cattle Company Van Newkirk Herefords Gardiner Angus Ranch Cow Camp Ranch Jungels Shorthorn Farms Ellingson Angus Edgar Brothers Angus Schaff Angus Valley Prairie Hills Gelbvieh Clear Springs Cattle Company CK Cattle Mrnak Hereford Ranch Frey Angus Ranch Hoffmann Angus Farms Topp Herefords River Creek Farms Upstream Ranch Gustin's Diamond D Gelbvieh Schiefelbein Farms Wasem Red Angus Raven Angus Krebs Ranch Yon Family Farms Chestnut Angus Eichacker Simmentals & JK Angus Windy Creek Cattle Company Pedersen Broken Heart Ranch Mar Mac Farms Warner Beef Genetics Arda Farms & Freeway Angus Leland Red Angus & Koester Red Angus Fast - Dohrmann - Strommen RBM Livestock Weber Land & Cattle FEATURING Dr. Tim Parks, D.V.M. Merck Animal Health https://www.merck-animal-health-usa.com/ @merckanimalhealth   Bryce Kelley Ritchey Livestock ID https://ritcheytags.com/ @RitcheyLivestockID   Kirk Donsbach: Stone X Financial https://www.stonex.com/   @StoneXGroupInc      Mark Van Zee  Livestock Market, Equine Market, Auction Time https://www.auctiontime.com/ https://www.livestockmarket.com/ https://www.equinemarket.com/ @LivestockMkt @EquineMkt @AuctionTime   Shaye Koester Casual Cattle Conversation https://www.casualcattleconversations.com/ @cattleconvos Questions & Concerns From The Field? Call or Text your questions, or comments to 707-RANCH20 or 707-726-2420 Or email RanchItUpShow@gmail.com FOLLOW Facebook/Instagram: @RanchItUpShow SUBSCRIBE to the Ranch It Up YouTube Channel: @ranchitup Website: RanchItUpShow.com https://ranchitupshow.com/ The Ranch It Up Podcast available on ALL podcasting apps. Rural America is center-stage on this outfit. AND how is that? Because of Tigger & BEC... Live This Western Lifestyle. Tigger & BEC represent the Working Ranch world by providing the cowboys, cowgirls, beef cattle producers & successful farmers the knowledge and education needed to bring high-quality beef & meat to your table for dinner. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner aka BEC here: TiggerandBEC.com https://tiggerandbec.com/ #RanchItUp #StayRanchy #TiggerApproved #tiggerandbec #rodeo #ranching #farming References https://www.stonex.com/ https://www.livestockmarket.com/ https://www.equinemarket.com/ https://www.auctiontime.com/ https://gelbvieh.org/ https://www.imogeneingredients.com/ https://alliedgeneticresources.com/ https://westwayfeed.com/ https://medoraboot.com/ http://www.gostockmens.com/ https://ranchchannel.com/ https://www.merck-animal-health-usa.com/species/cattle https://ritcheytags.com/ https://www.meatingplace.com/Industry/News/Details/113744

Peter Adams, Senior executive manager with consistent track record of high achievement in Europe, USA and Canada. Depth of experience in the building of technology based organizations, quickly developing and implementing strategies and creating market awareness. Experience developed through blue chip, startup, and consulting organizations plus management of independent business. Consistently exceeds targets within budget limits. Experience spans healthcare, semiconductors, software,IT services,systems and systems integrationSHOWNOTES:

Dr. Mary Barbera explores the latest in autism research, focusing on Dr. Karen Parker's study on intranasal vasopressin. Despite challenges, such as translating animal model research to human application, vasopressin shows promise in improving social behavior and reducing anxiety in children with autism. Supported by the Simons Foundation, this research highlights potential breakthroughs in autism treatment. Join the movement through initiatives like the SPARK program, fostering collaboration and hope for a brighter future in autism care.

In our latest episode, we venture into the heart of cardiology innovation, exploring groundbreaking studies that are reshaping how we approach common cardiovascular conditions.   STUDY #1: Our journey begins with a Lancet paper that looks at a potential alternative for treating supraventricular tachycardias (SVTs). Imagine a world where the distress of SVTs can be alleviated without ablation, a rush to the emergency department or the complexities of intravenous therapy. An intranasal medication might be the key, offering a beacon of hope for patients seeking simpler, yet effective solutions. But how effective is this approach, and what does it mean for the future of SVT management? Stambler, BS, Camm, AJ, Alings, M, et al. 2023. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): A multicentre, randomized trial. Lancet. 10396: 118–128. (https://doi.org/10.1016/S0140-6736(23)00776-6)   STUDY #2: Transitioning to the realm of antiplatelet therapy, we confront the longstanding question of P2Y12 inhibitors versus aspirin. Will these new findings tilt the balance and shift our approach to secondary coronary prevention? The nuances of this study prompt a deeper reflection on patient-centric care and the economics of new-generation medications.  Gragnano, F, Cao, D, Pirondini, L, et al. 2023. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2: 89–105. (https://doi.org/10.1016/j.jacc.2023.04.051)   STUDY #3: Lastly, we explore the potential of bempedoic acid in the landscape of cholesterol management, particularly for patients who are intolerant to statins. With cardiovascular diseases looming as a pervasive threat, the quest for alternative treatments is critical. We see if bempedoic acid could play a potential role in reducing major cardiovascular events, either alongside, or perhaps in lieu of, traditional statin therapy. Nissen, SE, Menon, V, Nicholls, SJ, et al. 2023. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2: 131–140. (https://doi.org/10.1001/jama.2023.9696) Kazi, DS. 2023. Bempedoic acid for high-risk primary prevention of cardiovascular disease: Not a statin substitute but a good plan B. JAMA. 2: 123–125. (https://doi.org/10.1001/jama.2023.9854)   Each study we discuss brings its own set of questions, implications, and possibilities for the future of cardiology. From the practicalities of new drug administrations to the cost and effectiveness of established therapies, this episode will get you up to speed!  For show notes, visit us at https://www.medmastery.com/podcasts/cardiology-podcast.

Neurons are cells that contain mitochondria. Photobiomodulation energizes neuronal mitochondria, triggering a cascade of beneficial cellular functions. Potential benefits are neuroprotective effects, self-repair mechanisms and enhanced functionality. Vielight's patented intranasal stimulation technology and microchip LED technology is an innovative tool for brain photobiomodulation developed by Vielight. My guest today is Vielight's CEO Dr. Lew Lim. Intranasal photobiomodulation is the most efficient method for light energy to reach the brain. Different from electrical and magnetic stimulation, photobiomodulation uses light energy (or photons) of specific wave lengths and power density to simulate cellular function.    Vagus Neuro Duo The Vielight Neuro Duo is is the result of years of engineering and research. Clinical research with our technology has produced improvements in cognition, memory and blood flow. The Vielight Neuro Duo comes with both Alpha and Gamma modes. Gamma (40Hz): focus, memory, brain energy.Alpha (10 Hz): relaxation and sleep improvement. Vagus Device Recently introduced is Vielight's Vagus device which enables non-invasive stimulation of the vagus nerve (VNS) via photobiomodulation (PBM). This device was engineered to enhance brain-gut connectivity.  For more information visit: https://www.vielight.com Enter Coupon Code healing4me to claim a 10% discount.   

People living with sickle cell disease can experience severe “pain crises”, or vaso-occlusive episodes (VOE), and are at increased risk for infections, strokes, heart failure, and other serious disease processes. In this 3 part series, we're talking with experts to learn more about sickle cell disease and its complications and how we can best advocate for and treat these patients in the ED. In part 1, we delved into assessment and management of patients presenting with VOE. In this episode, we focus specifically on kids presenting with VOE. We know these patients have usually exhausted their home pain control options and are still in excruciating pain when they arrive in the ED. We interviewed Dr. Chris Rees about his recent paper on the benefits of treating kids with VOE with an initial dose of intranasal fentanyl.  The results are pretty impressive!  Stay tuned for Part 3 of our series where we'll explore the management of other emergent presentations related to sickle cell disease! Did this episode change your practice? Let us know on social media @empulsepodcast or at ucdavisem.com Hosts: Dr. Sarah Medeiros, Associate Professor of Emergency Medicine at UC Davis Dr. Julia Magaña, Associate Professor of Pediatric Emergency Medicine at UC Davis Guests: Dr. Chris Rees, Assistant Professor of Pediatrics and Emergency Medicine at Emory University Resources: Rees CA, Brousseau DC, Ahmad FA, et al; SCD Arginine Study Group and PECARN. Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective. Am J Hematol. 2023 Apr;98(4):620-627. doi: 10.1002/ajh.26837. Epub 2023 Feb 6. PMID: 36606705; PMCID: PMC10023395.. Pediatric Emergency Care Applied Research Network (PECARN) ACEP Emergency Department Sickle Cell Care Coalition Resources ***** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

Uma vacina intranasal contra a Covid-19 desenvolvida no Brasil apresentou 100% de eficácia nos testes em camundongos, aponta artigo publicado na revista científica Vaccines. A pesquisa teve apoio da Fapesp e foi desenvolvida no Instituto de Ciências Biomédicas da Universidade de São Paulo (ICB-USP), em um convênio com a Fundação Oswaldo Cruz (Fiocruz). Também colaboraram pesquisadores da Faculdade de Ciências Farmacêuticas (FCF-USP), do Instituto de Medicina Tropical (IMT-USP) e da Universidade Federal do Rio de Janeiro (UFRJ).

RAPM Editor-in-Chief Brian Sites, MD, joins Hsiangkuo Yua, MD, PhD, and Aniket Natekar, MD, two coauthors of “Real-world study of intranasal ketamine for use in patients with refractory chronic migraine,” first published in May 2023. Dr. Hsiangkuo Yuan received his medical degree from National Yang-Ming University in Taipei, Taiwan, and a PhD in biomedical engineering at Duke University. He joined Jefferson Headache Center in 2014 as a research fellow, then completed a neurology residency and headache fellowship at Thomas Jefferson University. Dr. Yuan is currently an associate professor of neurology and the director of clinical research at the Jefferson Headache Center. He is also the vice chair of ASRA Headache SIG and an associate editor of RAPM. His research interests include real world analysis of novel migraine therapeutics and a fundamental understanding of CSF dynamics in patients with CSF high and low pressure headaches. Dr. Aniket Natekar pursued his medical education at the John A. Burns School of Medicine at the University of Hawaii in Honolulu. He attended Thomas Jefferson University Hospital in Philadelphia, where he completed his residency in general neurology, and then a fellowship in headache medicine at the Jefferson Headache Center. Dr. Natekar is currently a practicing neurologist with a subspecialty training in headache management. Migraine is a common and disabling headache disorder with huge societal implications in terms of human suffering and loss of productivity. The World Health Organization recognizes its importance by ranking it in seventh place among worldwide diseases causing disability. Refractory chronic migraine headache is a subset condition of migraines. As the name suggests, it is an extremely unfortunate situation with limited treatment options. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on Twitter @RAPMOnline. #headache #headachedisorder #migraine #refractorychronicmigraine #respiratorycomplications #intranasalketamine #regionalanesthesia #chronicpain #anesthesia #pain #painmanagement #MedEd #medicine

Comparative effectiveness of intranasal and parenteral vaccines for prevention of bovine respiratory disease in feedlot heifersAABP Podcast - Have You Herd? - RichesonRicheson et al PaperQuestions, comments, scathing rebuttals? -> themoosroom@umn.edu or call 612-624-3610 and leave us a message!Twitter -> @UMNmoosroom and @UMNFarmSafetyFacebook -> @UMNDairyYouTube -> UMN Beef and Dairy and UMN Farm Safety and HealthInstagram -> @UMNWCROCDairyExtension WebsiteAgriAmerica Podcast Directory

Intranasal administration of medications is on the rise for both on and off label uses. Dr. Mark Donaldson, Associate Principal and Dr. Philippe Mentler Senior Consulting Director, both at Vizient join host Gretchen Brummel for two episodes, sharing details on these drugs, their actions and indications.   Guest speakers: Mark Donaldson, BSP, RPH, PHARMD, FASHP, FACHE Associate Principal Vizient Philippe Mentler, PHARMD, BCPS Senior Consulting Director Vizient Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [00:33 - 02:50] Why you would choose intra-nasal administration of an agent over some of the other non-oral or non-IV routes [02:51 - 6:05] Some practical considerations people should be aware of, particularly when not to use these agents [6:06 - 7:12] Some of the implications for the pediatric population [7:13 - 12:10] What we have to look forward to in the future in this space [12:11 - 13:46] What our frontline pharmacy staff should know about these medications   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed  

Intranasal administration of medications is on the rise for both on and off label uses. Dr. Mark Donaldson, Associate Principal and Dr. Phillipe Mentler Senior Consulting Director, both at Vizient join host Gretchen Brummel for two episodes, sharing details on these drugs, their actions and indications.   Guest speakers: Mark Donaldson, BSP, RPH, PHARMD, FASHP, FACHE Associate Principal Vizient Phillipe Mentler, PHARMD, BCPS Senior Consulting Director Vizient Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [01:16 - 03:46] Why the nose is a good target for medication administration [03:47 - 5:49] Some things you need to consider when administering medications intra-nasally [5:50 - 8:13] Some of the labeled and off-label intra-nasal medications and their indications [8:14 - 9:15] What we should be thinking about in terms of safety [9:16 - 10:06] Wrong route, have you seen that in your practice, or have there been reports of that in the literature [10:07 - 15:10] How some of these drugs are used in dental medicine   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

In this episode, Dr. Osterholm and Chris Dall discuss the latest national and international COVID trends, an intranasal COVID vaccine candidate, and some recent findings on long COVID. Dr. Osterholm also answers an ID Query about the timing of COVID booster doses and shares two historic public health moments in our new "This Week in Public Health History" segment.

Date: June 15, 2023 Reference: Rees CA et al. Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective. American Journal of Hematology Jan 2023 Guest Skeptic: Dr. Amy Drendel is a pediatric emergency medicine physician and physician scientist at Children's Wisconsin. […] The post SGEM#406: Homeward Bound…after a dose of Intranasal Fentanyl for Sickle Cell Vaso-occlusive Pain first appeared on The Skeptics Guide to Emergency Medicine.

#neurofeedback #neurofeedbackpodcast #photobiomodulation #mentalhealthpodcast #shorts Dr. Marvin Berman founder of QuietMIND Foundation joins Jay Gunkelman the Man who has read over 500,000 Brain Scans, Author of iMinds Dr. Mari Swingle, John Mekrut founder of The Balanced Brain and Pete Jansons on the NeuroNoodle Network podcast to discuss photobiomodulation and in this short clip Dr Marvin Berman explains how Intranasal Light can kill Covid and MRSA Main Clip https://youtu.be/_vcsdBMdEwYhttps://www.marvinbermanphd.com/https://www.quietmindfdn.org/ @neuronic --- Send in a voice message: https://podcasters.spotify.com/pod/show/neuronoodle/message Support this podcast: https://podcasters.spotify.com/pod/show/neuronoodle/support

In this episode Dr's J and Santhosh continue their series on the senses of medicine by discussing smell! Along the way they cover their recovery from c2e2, the memorable scent of anatomy lab, disease smell pokemon, bacteria wine snobbery, the miasma theory, human noses detecting disease, the discovery of smell, how olfaction works, disorder of smelling, sniffin sticks, covid, body odor, old people smell, smell rehab and more! So sit back and take a whiff of all this knowledge on smells we are sending your way this week!Further Readinghttps://journals.sagepub.com/doi/abs/10.1177/0956797613515681https://pubmed.ncbi.nlm.nih.gov/33493729/#:~:text=For%20all%20anosmia%20and%20dysgeusia,taste%20was%20within%20a%20week.https://pubmed.ncbi.nlm.nih.gov/28434127/#:~:text=Intranasal%20vitamin%20A%20at%20a,of%20post%2Dinfectious%20olfactory%20loss.https://www.njmonline.nl/getpdf.php?id=1330https://onlinelibrary.wiley.com/doi/full/10.1111/exd.13259Nguyen TP, Patel ZM. Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018 Sep;8(9):977-981.Support Us spiritually, emotionally or financially here! or on ACAST+Twitter: @doctorjcomedy @toshyfroInstagram: @travelmedicinepodcastSpotify: https://open.spotify.com/show/28uQe3cYGrTLhP6X0zyEhTFacebook: facebook.com/travelmedicinepodcastPatreon: https://www.patreon.com/travelmedicinepodcast Supporting us monthly has all sorts of perks! You get ad free episodes, bonus musical parody, behind the scenes conversations not available to regular folks and more!! Your support helps us to pay for more guest interviews, better equipment, and behind the scenes people who know what they are doing! https://plus.acast.com/s/travelmedicinepodcast. Hosted on Acast. See acast.com/privacy for more information.

In this week's podcast, Neurology Today's editor-in-chief discusses the newly approved zavegepant for migraine, the potential/caveats of ultrasound ablation for Parkinson's disease, the transational potential of a new therapeutic target for Duchenne muscular atrophy.

JAMA Pediatrics Editors' Summary by Dimitri A. Christakis, MD, MPH, Editor in Chief, and Alison A. Galbraith, MD, MPH, Associate Editor, for the April 3, 2023, issue. Related Content: Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis Changes in Body Mass Index Among School-Aged Youths Following Implementation of the Healthy, Hunger-Free Kids Act of 2010

Two diabetes drugs permanently discontinued; Consistent reduction in schizophrenia symptoms with an investigational Tx; Positive results for investigational Social Anxiety Disorder therapy; High-concentration Humira biosimilar approved; Sleep apnea treatment expanded for pediatrics with Down syndrome

Show notes at pharmacyjoe.com/episode799. In this episode, I’ll discuss an article about intranasal dexmedetomidine for procedural sedation in the ED. The post Episode 800: Intranasal Dexmedetomidine for Procedural Sedation in the ED appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode799. In this episode, I’ll discuss an article about intranasal dexmedetomidine for procedural sedation in the ED. The post Episode 800: Intranasal Dexmedetomidine for Procedural Sedation in the ED appeared first on Pharmacy Joe.

How can intranasal antihistamines help patients with perennial allergic rhinitis? Drs Vega and Corren discuss. Credit available for this activity expires: 1/25/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/986413?ecd=bdc_podcast_libsyn_mscpedu

In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don't have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.Presenters:Aatif Husain, MDProfessorDivision of Epilepsy, Sleep and Clinical NeurophysiologyDepartment of NeurologyDuke University Medical CenterDurham, North CarolinaJohn Stern, MDProfessorNeurologyGeffen School of Medicine, UCLADirectorEpilepsy Clinical ProgramUCLA Department of NeurologyLos Angeles, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.For additional activities in this program, visit https://bit.ly/3GiLlu4.

00:00 – 01:50  Welcome and Introductions  1:50 -  2:53   Age categories for young calf vaccinations 2:53 – 5:07  What diseases can we vaccinate young calves for? 5:07 – 9:03  Immune system development in the calf 9:03 -  11:33 The effect of maternal immunity on vaccine response 11:33 - 17:45     Intranasal vs Injectable Vaccines: What's the difference? 17:45 – 19:30 Evidence of vaccine protection against summer pneumonia of calves 19:30 – 21:00     Intranasal vaccines currently available in Canada 21:00 – 25:08  Best practices for administering modified live intranasal vaccines 25:08 – 28:10 The importance of working with your veterinarian to design a vaccination protocol Links to Related InformationVaccination of the Beef Herd  https://www.beefresearch.ca/topics/vaccination-of-the-beef-herd/BCRC Webinar on Using Nasal Vaccines Effectively  https://www.beefresearch.ca/webinars/using-nasal-vaccines-effectively/Blog article featuring intranasal vaccines  https://www.beefresearch.ca/blog/intranasal-vaccines-are-timely-and-effective/

What are some of the major differences between intravenous or IV ketamine and intranasal esketamine? How are you building on these research findings and what associated avenues have been explored? In this episode, we interview the poster winner from last year's NEI Congress, Dr. Balwinder Singh on his research comparing intravenous ketamine and intranasal esketamine. The study, conducted at Mayo Clinic rendered interesting findings that may be important for clinicians. Dr. Balwinder Singh is a Consultant and Assistant professor in the Department of Psychiatry at Mayo Clinic in Rochester, Minnesota. He is a psychiatrist specializing in mood disorders, and his research is focused on novel treatments for treatment-resistant depression and identifying biomarkers for ketamine response.  He is also involved in the ketamine and esketamine clinic practice at the Mayo Clinic Depression Center.   This is one of the first studies to highlight a faster response to intravenous ketamine as compared to intranasal esketamine in an observational study.

Dean, Dave and Andy start this week off by talking about today being National Cheeseburger day. Then Dave gives his Far Flung Forecast! Dr. Kevin Most, Chief Medical Officer at Northwestern Central DuPage Hospital, joins Dean for this week's regular COVID-19 segment.  Dr. Most talks about what he thinks of the new Intranasal vaccine for COVID and if […]

Some allies of former President Donald Trump are urging him to publicly release surveillance footage of FBI agents executing a search warrant on his Mar-a-Lago residence, a proposal that has drawn mixed reaction inside his orbit. Rochelle Walensky, director of the Centers for Disease Control and Prevention, outlined a broad plan to overhaul the organization's structure and operations in light of what she said was its failure to respond efficiently to the COVID-19 pandemic, according to media reports. Intranasal vaccination produces potent systemic immunity against HIV and SARS-CoV-2 in animal models.See omnystudio.com/listener for privacy information.

A relatively new vaccine for cattle from Merck Animal Health is combining both bacterial and viral protection in one intranasal dose, reducing the number of instances producers have to administer vaccines to each animal. Bovilis Nasalgen 3-PMH, simply called Nasalgen, has been on the market for roughly one year and combines three virals and two... Read More

Contributor: Aaron Lessen, MD Educational Pearls: Intranasal medication administration is a convenient, quick, and relatively painless option for pediatric patients Often used as an initial medication to help control pain in children prior to establishing an IV Using an atomizer is preferred when administering intranasal medications The syringe should be angled towards the ipsilateral eye or occiput rather than straight upwards Do not administer more than 1 mL of fluid per nostril as volumes greater than 1 mL are not sufficiently absorbed Intranasal medication doses differ from the traditional IV dosages and have a slower onset of action References Del Pizzo J, Callahan JM. Intranasal medications in pediatric emergency medicine. Pediatr Emerg Care. 2014;30(7):496-501; quiz 502-494. Fantacci C, Fabrizio GC, Ferrara P, Franceschi F, Chiaretti A. Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room. Eur Rev Med Pharmacol Sci. 2018;22(1):217-222. Rech MA, Barbas B, Chaney W, Greenhalgh E, Turck C. When to Pick the Nose: Out-of-Hospital and Emergency Department Intranasal Administration of Medications. Ann Emerg Med. 2017;70(2):203-211. Schoolman-Anderson K, Lane RD, Schunk JE, Mecham N, Thomas R, Adelgais K. Pediatric emergency department triage-based pain guideline utilizing intranasal fentanyl: Effect of implementation. Am J Emerg Med. 2018;36(9):1603-1607.   Summarized by Mark O'Brien, MS4 | Edited by John Spartz, MD & Erik Verzemnieks, MD   The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at https://emergencymedicalminute.org/cme-courses/ and create an account.  Donate to EMM today!

Children with Autism Spectrum Disorder (ASD) face several challenges due to deficits in social function and communication with distinct patterns of behaviors that can be difficult to manage and even disruptive. Laser and light therapy can be used for transcranial photobiomodulation to enhance mitochondrial activity and ATP synthesis, increasing functional activity and cognition. Listen along as Dr. Rountree and Kristi discuss a 2022 study on ASD and laser therapy, how the treatment was administered, what kind of side effects may occur and what the outcomes were for the ASD patients. Also, learn what steps you can take today to help your autistic child. We have begun live-streaming this podcast. Watch this episode on Facebook right here, and see the next episode LIVE in two weeks!Mentioned in this episode:Transcranial Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder (ASD): A Retrospective Study.VielightVisit the LTI website for more information and to find a laser therapy provider near you.  Are you a healthcare provider?Laser Therapy Institute Podcast  YouTube ChannelHealing at the Speed of Light

Dr. Richard Novak, head of the Division of Infectious Diseases at UI Health, spoke with Steve Dale on the prospects of using an intranasal COVID-19 vaccine instead of the standard shot. Dr. Novak also answered listener questions about vaccine-triggered M.S., the stealth omicron variant, BA.2, the possibility of COVID-19 becoming an endemic, and more!

Thomas and Angelica discuss three recent developments in vaccines, the science of how they work, the history of their development, and the politics surrounding them.   Subscribe in Apple Podcasts, Spotify, or wherever you're listening right now.   Facebook: https://www.facebook.com/objectivestandard Twitter: https://twitter.com/ObjStdInstitute LinkedIn: https://www.linkedin.com/company/objectivestandardinstitute/   Here are some links related to the information discussed on the show:   3D printed vaccine patch: https://scitechdaily.com/3d-printed-vaccine-patch-offers-vaccination-without-a-shot-outperforms-needle-jab-in-boosting-immunity/   Intranasal vaccine for COVID-19: https://www.cell.com/iscience/fulltext/S2589-0042(21)01005-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004221010051%3Fshowall%3Dtrue   Antibodies against malaria: https://www.science.org/content/article/landmark-study-finds-artificial-antibodies-can-protect-against-malaria   History of vaccines: https://www.immune.org.nz/vaccines/vaccine-development/brief-history-vaccination   Variolation: https://www.nlm.nih.gov/exhibition/smallpox/sp_variolation.html   Diseases eradicated by vaccines: https://www.historyofvaccines.org/index.php/content/articles/disease-eradication   Tetanus: https://ourworldindata.org/tetanus Immunity and challenges: https://www.livescience.com/why-lifelong-immunity.html

The hormone is no better than placebo at boosting social behavior in autistic children, according to a new study, but it may still benefit a subset of people with the condition.

EMS A to Z: Journal Club – Intranasal Midazolam for Pediatric Seizures Show Notes: From your hosts, Dr. Josh Gaither, Dr. Amber Rice, and Dr. Rachel Munn   Pediatric Seizures: According to the American Academy of Pediatrics, epilepsy affects up to 1% of children. It's location dependent, but pediatric EMS calls can make up about 13% of our calls, with 5 – 8 % of those being for seizures.  https://www.acep.org/how-we-serve/sections/quality-improvement--patient-safety/newsletters/february-2016/pediatric-seizure-management-in-the-out-of-hospital-environment/ Recognizing and rapidly treating pediatric seizures or status epilepticus can decrease the morbidity associated with this disease process. What are the best medication and route to treat pediatric seizure?   In our system and administrative guidelines, we are currently using IM midazolam as our first line medication. This decision was informed largely by the RAMPART What are the other therapeutic options out there?  IV, IM, IN, buccal midazolam IV or PR diazepam IV lorazepam What is the new study we're discussing today?  Whitfield D, Bosson N, Kaji AH, Gausche-Hill M. The Effectiveness of Intranasal Midazolam for the Treatment of Prehospital Pediatric Seizures: A Non-inferiority Study. Prehosp Emerg Care. 2021 Mar 29:1-9. doi: 10.1080/10903127.2021.1897197. Epub ahead of print. PMID: 33656973. Study details: This was a retrospective study looking at IN vs IM/IV midazolam and whether or not redosing of benzodiazepine was required in the prehospital setting. >2,000 patients with a median age of 6 years were evaluated in the study. 25% vs 14% of patients receiving IN vs IV/IM/IO midazolam required re-dosing. While it is tempting to say that IN midazolam just isn't as effective for seizure control as the other routes, we must consider that the dose used was only 0.1mg/kg for all routes, whereas in other studies evaluating IN midazolam, a 0.2mg/kg dose was used. Perhaps the dose was just too small. Additionally, the outcome measured wasn't a true patient centered outcome and we do not have follow up data on the patients' hospital courses, etc.

In this first episode of the Society for Pediatric Sedation (SPS) Podcast, we will be discussing the use of intranasal medication in procedural sedation for children. We will be joined by Dr. Carmen Sulton, the Assistant Professor of Pediatrics at Emory University School of Medicine and Director of Children Sedation Services at Egleston campus in Atlanta. Dr. Sulton is well published in the field of pediatric procedural sedation including a recent paper on the use of intranasal Dexmedetomidine published in Pediatric Emergency Care in 2020. The paper uses patient outcomes data from the Pediatric Sedation Research Consortium database, the research arm of the Society for Pediatric Sedation.In our case today, we have a five months old infant who requires an MRI of his brain. The patient is an ex-32 week premature infant with a history of difficult IV access. There's no history of upper respiratory tract infection, no snoring, heart disease, or any medication allergy in this infant. The MRI is needed for a focal seizure that occured two weeks ago and the patient doesn't require an IV since this is not a contrasted MRI. Dr. Sulton will generously share with us why intranasal medications are needed in procedural sedation and so much more, so don't miss out if this is a topic of interest for you.Meet your hosts:Pradip Kamat, MD, MBA - Associate Professor of Pediatrics and Critical Care Physician at Emory University School of Medicine and Children's Healthcare of Atlanta/Egleston.Anne Stormorken, MD - Professor of Pediatrics and Critical Care Physician at UH Rainbow Babies and Children's Hospital and Case Western Reserve School of Medicine of Cleveland, OH.Show HighlightsDiving into how intranasal medications work (01:58)Circumstances where intranasal medications must not be used for procedural sedation (04:35)How she uses Dexmedetomidine and Midazolam (06:28)Research findings on the success rate with the use of intranasal medications (09:14)Other medications that can be used intranasally for procedural sedation (11:42)Optimizing the efficacy of intranasal medications when delivering them (12:09)Giving IV sedation where there is intranasal medication failure (13:23)Large dataset studies that support the successful use of intranasal medications in procedural sedation (14:23)Additional ResourcesThe Use of Intranasal Dexmedetomidine and Midazolam for Sedated Magnetic Resonance Imaging in Children